Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jin Wang, Dongying Liao, Xuemin Zhang, Changhong Miao & Kuang Chen. (2023) Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review. Breast Cancer: Targets and Therapy 15, pages 281-294.
Read now
Read now
Shuai Jiang, Shuai Geng, Xinyue Gao, Tong Liu, Xinyu Luo, Nan Wang, Ning Shi & Mei Dong. (2023) Evaluation of HER-2 positive breast cancer treated with dual-targeted treatment of trastuzumab plus pertuzumab. Immunopharmacology and Immunotoxicology 45:5, pages 616-625.
Read now
Read now
Yongchao Yu, Jin Wang, Dongying Liao, Dou Zhang, Xiaojiang Li, Yingjie Jia & Fanming Kong. (2022) Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer. Breast Cancer: Targets and Therapy 14, pages 417-432.
Read now
Read now
Guangwen Liu, Zhongnan Xu, Wei Yang, Jinling Xue, Yanli Wang, Zhengzhi Liu, Yingzi Cui, Xinyao Qu, Tianying Chang, Shuang Yu, Yang Cheng, Yannan Zhou, Jiahui Chen, Qing Ren, Wanhua Wang, Qiaohuan Deng, Zeyu Wang & Haimiao Yang. (2022) A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects. Expert Opinion on Biological Therapy 22:2, pages 187-195.
Read now
Read now
Andrea Luque-Bolivar, Erika Pérez-Mora, Victoria Eugenia Villegas & Milena Rondón-Lagos. (2020) Resistance and Overcoming Resistance in Breast Cancer. Breast Cancer: Targets and Therapy 12, pages 211-229.
Read now
Read now
Articles from other publishers (35)
Puneet K Singh & Razvan C Stan. (2023) Enhanced binding at fever temperatures of HER2 in complex with trastuzumab and pertuzumab. Immunotherapy 15:13, pages 1021-1027.
Crossref
Crossref
Faizan Fazal, Muhammad Nauman Bashir, Maham Leeza Adil, Usama Tanveer, Mansoor Ahmed, Taha Zahid Chaudhry, Ali Ahmad Ijaz & Muhammad Haider. (2023) Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials. Cureus.
Crossref
Crossref
Shima Yousefi Rizi, Sun-Hee Kim, Jung-Hoon Lee & Hee-Jin Jeong. (2023) Generation of an scFv-type Quenchbody Against HER2 for Sensitive Detection of Human Breast Cancer. KSBB Journal 38:1, pages 35-45.
Crossref
Crossref
Oladapo Olaleye, Baubek Spanov, Peter Bults, Anna van der Voort, Natalia Govorukhina, Gabe S. Sonke, Peter Horvatovich, Nico C. van de Merbel & Rainer Bischoff. (2023) Biotransformation of Trastuzumab and Pertuzumab in Breast Cancer Patients Assessed by Affinity Enrichment and Ion-Exchange Chromatography. Drug Metabolism and Disposition 51:2, pages 249-256.
Crossref
Crossref
Sandra M. Swain, Mythili Shastry & Erika Hamilton. (2022) Targeting HER2-positive breast cancer: advances and future directions. Nature Reviews Drug Discovery 22:2, pages 101-126.
Crossref
Crossref
Young Hun Chung, Britney A. Volckaert & Nicole F. Steinmetz. (2023) Development of a Modular NTA:His Tag Viral Vaccine for Co-delivery of Antigen and Adjuvant. Bioconjugate Chemistry 34:1, pages 269-278.
Crossref
Crossref
Pingxin Zhang, Ren Mao, Chuhan Zhang, Yun Qiu & Minhu Chen. (2023) Gastrointestinal injury induced by immunomodulators: A review article. Therapeutic Advances in Gastroenterology 16, pages 175628482311585.
Crossref
Crossref
Kammila Martins Nicolau Costa, Demis Ferreira de Melo, Ingrid Larissa da Silva Soares, Bolívar Ponciano Goulart de Lima Damasceno & João Augusto Oshiro-Júnior. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
30
.
Mirela Gherghe, Alexandra Maria Lazar, Mario-Demian Mutuleanu, Cristian Ioan Bordea, Sinziana Ionescu, Raluca Ioana Mihaila, Cristina Petroiu & Adina Elena Stanciu. (2022) Evaluating Cardiotoxicity in Breast Cancer Patients Treated with HER2 Inhibitors: Could a Combination of Radionuclide Ventriculography and Cardiac Biomarkers Predict the Cardiac Impact?. Cancers 15:1, pages 207.
Crossref
Crossref
Desh Deepak Singh, Hae-Jeung Lee & Dharmendra Kumar Yadav. (2022) Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer. Frontiers in Pharmacology 13.
Crossref
Crossref
Joshua Tobias, Mirjana Drinić, Anna Schmid, Anastasiya Hladik, Martin L. Watzenböck, Claire Battin, Erika Garner-Spitzer, Peter Steinberger, Michael Kundi, Sylvia Knapp, Christoph C. Zielinski & Ursula Wiedermann. (2022) Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer. Cancers 14:22, pages 5678.
Crossref
Crossref
Maciej Borówka, Stanisław Łącki-Zynzeling, Michał Nicze, Sylwia Kozak & Jerzy Chudek. (2022) Adverse Renal Effects of Anticancer Immunotherapy: A Review. Cancers 14:17, pages 4086.
Crossref
Crossref
Jiangang Sun, Xiaojing Li, Peng Chen & Yongshun Gao. (2022) From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. Journal of Inflammation Research Volume 15, pages 4061-4085.
Crossref
Crossref
Santiago Moragon, Cristina Hernando, Maria Teresa Martinez-Martinez, Marta Tapia, Belen Ortega-Morillo, Ana Lluch, Begoña Bermejo & Juan Miguel Cejalvo. (2022) Immunological Landscape of HER-2 Positive Breast Cancer. Cancers 14:13, pages 3167.
Crossref
Crossref
Sreeja Raj MenonArpit MitraAvik ChakrabortyMegha TawateSudeep SahuSutapa RakshitSujay GaikwadGeetanjali DhotreArchana DamleSharmila Banerjee. (2022)
Clinical Dose Preparation of [
177
Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [
177
Lu]LuCl
3
for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression
. Cancer Biotherapy and Radiopharmaceuticals 37:5, pages 384-402.
Crossref
Crossref
Li-Chung Tsao, Erika J. Crosby, Timothy N. Trotter, Junping Wei, Tao Wang, Xiao Yang, Amanda N. Summers, Gangjun Lei, Christopher A. Rabiola, Lewis A. Chodosh, William J. Muller, Herbert Kim Lyerly & Zachary C. Hartman. (2022) Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis. JCI Insight 7:6.
Crossref
Crossref
Chih-Chiang Hung, I-Chen Tsai, Chiann-Yi Hsu & Hsin-Chen Lin. (2022) Clinical Outcomes of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 Breast Cancer Patients: A Single-Center Retrospective Study. Journal of Clinical Medicine 11:5, pages 1434.
Crossref
Crossref
J. Tobias, E. Garner-Spitzer, M. Drinić & U. Wiedermann. (2022) Vaccination against Her-2/neu, with focus on peptide-based vaccines. ESMO Open 7:1, pages 100361.
Crossref
Crossref
Ghmkin Hassan & Masaharu Seno. 2022. Cancer Stem Cell Markers and Related Network Pathways. Cancer Stem Cell Markers and Related Network Pathways
65
81
.
Glauco Baiocchi Neto, Fabiana Baroni Alves Makdissi & Renato Cagnacci Neto. 2022. Vascular Surgery in Oncology. Vascular Surgery in Oncology
163
200
.
Linxi Zhu, Qingxin Mu, Jesse Yu, James I. Griffin, Xiaolin Xu & Rodney J. Y. Ho. (2021) ICAM-1 Targeted Drug Combination Nanoparticles Enhanced Gemcitabine-Paclitaxel Exposure and Breast Cancer Suppression in Mouse Models. Pharmaceutics 14:1, pages 89.
Crossref
Crossref
Natalia Magdalena Lisiak, Izabela Lewicka, Mariusz Kaczmarek, Jacek Kujawski, Barbara Bednarczyk-Cwynar, Lucjusz Zaprutko & Blazej Rubis. (2021) Oleanolic Acid’s Semisynthetic Derivatives HIMOXOL and Br-HIMOLID Show Proautophagic Potential and Inhibit Migration of HER2-Positive Breast Cancer Cells In Vitro. International Journal of Molecular Sciences 22:20, pages 11273.
Crossref
Crossref
Marc Peeters, David Planchard, Mark Pegram, João Gonçalves, François Bocquet & Harah Jang. (2021) Biosimilars in an era of rising oncology treatment options. Future Oncology 17:29, pages 3881-3892.
Crossref
Crossref
Yen-Shen Lu, Andrea Wong & Hee-Jeong Kim. (2021) Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women. Frontiers in Oncology 11.
Crossref
Crossref
Agnieszka Gornowicz, Wojciech Szymanowski, Robert Czarnomysy, Krzysztof Bielawski & Anna Bielawska. (2021) Anti-HER2 monoclonal antibodies intensify the susceptibility of human gastric cancer cells to etoposide by promoting apoptosis, but not autophagy. PLOS ONE 16:8, pages e0255585.
Crossref
Crossref
Sergiusz Łukasiewicz, Marcin Czeczelewski, Alicja Forma, Jacek Baj, Robert Sitarz & Andrzej Stanisławek. (2021) Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. Cancers 13:17, pages 4287.
Crossref
Crossref
Arya Bhushan, Andrea Gonsalves & Jyothi U. Menon. (2021) Current State of Breast Cancer Diagnosis, Treatment, and Theranostics. Pharmaceutics 13:5, pages 723.
Crossref
Crossref
Katalin Boér, Zsuzsanna Kahán, László Landherr, Tibor Csőszi, Károly Máhr, Ágnes Ruzsa, Zsolt Horváth, Barna Budai & Gábor Rubovszky. (2021) Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience. Pathology and Oncology Research 27.
Crossref
Crossref
Yun Lu, Meng Li, Adriana V. F. Massicano, Patrick N. Song, Ameer Mansur, Katherine A. Heinzman, Benjamin M. Larimer, Suzanne E. Lapi & Anna G. Sorace. (2021) [89Zr]-Pertuzumab PET Imaging Reveals Paclitaxel Treatment Efficacy Is Positively Correlated with HER2 Expression in Human Breast Cancer Xenograft Mouse Models. Molecules 26:6, pages 1568.
Crossref
Crossref
Iago Dillion Lima Cavalcanti & José Cleberson Santos SoaresIago Dillion Lima Cavalcanti & José Cleberson Santos Soares. 2021. Advances in Cancer Treatment. Advances in Cancer Treatment
79
89
.
Agneta Månsson Broberg, Jürgen Geisler, Suvi Tuohinen, Tanja Skytta, Þórdís Jóna Hrafnkelsdóttir, Kirsten Melgaard Nielsen, Elham Hedayati, Torbjørn Omland, Birgitte V. Offersen, Alexander R. Lyon & Geeta Gulati. (2020) Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer. Current Heart Failure Reports 17:6, pages 397-408.
Crossref
Crossref
Laura Orlando, Vito Lorusso, Francesco Giotta, Massimo Di Maio, Paola Schiavone, Palma Fedele, Annamaria Quaranta, Chiara Caliolo, Mariangela Ciccarese, Margherita Cinefra, Sante Romito, Salvatore Pisconti, Salvatore del Prete, Michele Aieta, Daniele Rizzi, Evaristo Maiello, Giuseppe Colucci & Saverio Cinieri. (2020) Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). The Breast 53, pages 18-22.
Crossref
Crossref
Claudia Omarini, Stefania Bettelli, Samantha Manfredini, Monica Barbolini, Chrystel Isca, Giulia Cortesi, Antonino Maiorana, Giovanni Tazzioli, Massimo Dominici & Federico Piacentini. (2020) Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy. Translational Oncology 13:9, pages 100794.
Crossref
Crossref
C.H. Barcenas, S.A. Hurvitz, J.A. Di Palma, R. Bose, A.J. Chien, N. Iannotti, G. Marx, A. Brufsky, A. Litvak, E. Ibrahim, R.H. Alvarez, M. Ruiz-Borrego, N. Chan, Y. Manalo, A. Kellum, M. Trudeau, M. Thirlwell, J. Garcia Saenz, D. Hunt, R. Bryce, L. McCulloch, H.S. Rugo, D. Tripathy, A. Chan, L. Carcas, A. Castrellon, D. Chan, K. Cheong, B. Choi, M. Coleman, A. Conlin, R. Dichmann, D. Ellison, N. Erickson, I. Gore, V. Hansen, D. Huang, D. Hufnagel, F. Kass, S.D. Kendall, M. Kozloff, W. Lawler, K.D. Nahum, B. Pistilli, E. Reyes, J. Seeger, R. Somer, E. Tan Chiu, G. Thomas, K. Tkaczuk, I. Vaziri, J. Wade & M. Wilkinson. (2020) Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Annals of Oncology 31:9, pages 1223-1230.
Crossref
Crossref
Yihui Chai, Yunzhi Chen, Wen Li, Zhong Qin, Jie Gao, Zhibin Jiang, Yuhong Ge, Liancheng Guan, Mengzhi Zhang, Huaiquan Liu, Haiyang Yu, Qingxue Wang & Changfu Yang. (2020) Efficacy and Safety of Aidi Injection as an Adjuvant Therapy on Advanced Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evidence-Based Complementary and Alternative Medicine 2020, pages 1-8.
Crossref
Crossref